Researchers from the Indian Institute of Technology Madras (IIT Madras), in collaboration with Monash University and Deakin University, Australia, have developed an advanced nanoinjection drug delivery platform that could significantly improve the safety and effectiveness of breast cancer treatment. By enabling precise, sustained, and intracellular drug delivery, this approach addresses long-standing limitations of conventional cancer therapies.
Addressing Limitations of Conventional Cancer Treatment
Breast cancer continues to be one of the leading causes of cancer-related mortality among women worldwide. Although chemotherapy and radiation remain standard treatment options, they often expose healthy tissues to systemic toxicity, leading to severe side effects. Therefore, there is an urgent need for targeted therapeutic strategies that selectively kill cancer cells while preserving normal tissue.
A Dual-Technology Nanoinjection Strategy
To overcome these challenges, the India–Australia research team developed a novel nanoinjection system that combines nanoarchaeosome-based drug encapsulation with silicon nanotube (SiNT)–mediated intracellular delivery. Specifically, the researchers loaded the anticancer drug doxorubicin into thermally stable nanoarchaeosomes (NAs) and delivered them directly into cancer cells using vertically aligned SiNTs etched onto a silicon wafer.
As a result, this integrated design enables precise drug injection into cells while ensuring sustained and controlled drug release. Importantly, the silicon nanotube architecture offers inherent biocompatibility and non-toxicity, eliminating the need for additional surface modifications commonly required in carbon- or titanium-based nanotube systems.
Enhanced Efficacy with Reduced Toxicity
Experimental findings demonstrated that the Nanoarchaeosome-Doxorubicin–Silicon Nanotube (NAD-SiNT) platform induced strong cytotoxic effects against MCF-7 breast cancer cells while sparing healthy fibroblasts. Furthermore, the system triggered cell-cycle arrest and necrosis specifically in cancer cells.
In addition, the researchers observed a significant reduction in angiogenesis—the formation of new blood vessels that support tumour growth. The NAD-SiNTs downregulated key pro-angiogenic factors, thereby limiting tumour progression through multiple therapeutic mechanisms.
Superior Potency at Lower Drug Doses
Notably, the nanoinjection platform demonstrated a 23-fold lower inhibitory concentration (IC50) compared to free doxorubicin. This enhanced potency allows effective cancer cell killing at much lower drug doses, which could directly translate into fewer side effects, improved patient tolerance, and reduced treatment costs.
Moreover, the system achieved long-term drug release for up to 700 hours, successfully addressing common drawbacks of nanocarrier systems such as burst release and poor drug retention.
Clinical and Societal Significance
Highlighting the broader implications of the work, Dr. Swathi Sudhakar, Assistant Professor and Faculty Advisor for Clinical Engineering at IIT Madras, emphasised its relevance for resource-limited settings. She noted that targeted delivery of smaller drug doses with higher efficacy could make advanced cancer treatment more affordable and accessible in low- and middle-income countries like India. Additionally, the platform aligns with national goals of developing cost-effective healthcare innovations and holds promise for adaptation to other cancer types.
English and Tamil bytes of Dr. Swathi Sudhakar explaining the research are available for viewing and download.
Pathway Toward Clinical Translation
As per the IIT Madras press release, the proof-of-concept has been successfully demonstrated in in vitro cell culture models and ex ovo chick embryo models, confirming both safety and therapeutic effectiveness. Building on this foundation, the next phase of research will focus on in vivo validation, long-term toxicity assessments, and regulatory evaluations.
Commenting on future directions, Dr. Roey Elnathan from Deakin University stated that the platform represents a modular drug delivery system with potential applicability across multiple cancer types. Meanwhile, Prof. Nicolas H. Voelcker from Monash University expressed confidence that this patented technology could reach clinical translation within the next five years.
Publication and Collaborative Effort
The findings were published in Advanced Materials Interfaces, a peer-reviewed journal focused on functional materials and surface technologies. The paper was co-authored by Kaviya Vijayalakshmi Babunagappan, Subastri Ariraman, Jann Harberts, Vimalraj Selvaraj, Mukilarasi Bedatham, Narendran Sekar, Nicolas H. Voelcker, Roey Elnathan, and Swathi Sudhakar.
The interdisciplinary research was supported by the IIT Madras–Deakin Joint Research Initiative, the Alexander von Humboldt Foundation, and the Australian Research Council, with contributions from the Melbourne Centre for Nanofabrication.
Toward Smarter and Safer Cancer Care
Overall, this nanoinjection-based drug delivery strategy marks a significant advance in precision nanomedicine. By combining high precision, thermal stability, prolonged drug release, and excellent biocompatibility, the platform has the potential to redefine cancer therapy—making it safer, smarter, and more accessible for patients worldwide.